ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the publication of a clinical study supporting the FDA approval of its Parsortix PC1 system for isolating circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The study, published in the Journal of Experimental & Clinical Cancer Research, demonstrated the system's ability to capture and harvest CTCs from MBC patient blood samples for downstream analysis.

Key findings include:

• CTCs were identified in 45% of MBC patients
• CTC clusters were found in 56% of CTC-positive patients
• 70% of detected CTCs did not express the epithelial marker EpCAM

This data supported ANGLE's successful FDA De Novo request for the Parsortix PC1 system's classification as a Class II medical device in 2022.

ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.

On July 12, 2024, Angle PLC, a UK-based company, announced a significant change in its major shareholdings. Dermot Keane, based in London, UK, has crossed the 5% threshold, increasing his voting rights from 4.90% to 8.09%, amounting to 26,110,422 voting rights. The notification was triggered by an acquisition of voting rights, with the official threshold crossing occurring on June 5, 2024. This information was published through the London Stock Exchange's Regulatory News Service (RNS), approved by the Financial Conduct Authority (FCA). No other financial instruments or changes in voting rights breakdown were reported.

Angle PLC, a leading liquid biopsy company, announced that all resolutions were passed at its Annual General Meeting held on July 11, 2024. This development confirms shareholder support for the company's strategic direction and operational plans. The resolutions covered various governance and corporate matters, underscoring the company’s commitment to advancing its liquid biopsy technologies.

For more information, stakeholders can contact Angle PLC at +44 (0) 1483 343434 or Berenberg, the company's NOMAD and Broker, at +44 (0) 20 3207 7800.

ANGLE plc, a leader in liquid biopsy solutions for CTCs, announced the posting of its 2023 Annual Report and Financial Statements. The report, covering the year ending December 31, 2023, is available on the company's website. Shareholders have been invited to the Annual General Meeting (AGM) scheduled for July 11, 2024, at the Surrey Technology Centre. The AGM will include a business update following formal proceedings. This announcement is significant for stakeholders tracking corporate governance and financial performance of ANGLE plc.

ANGLE announces the showcasing of its Parsortix system and assays at the European Association for Cancer Research (EACR) 2024 Annual Congress.

The company highlights two key presentations: the dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for genetic profiling in ovarian, breast, and lung cancer patients, and the use of its DNA Damage Response (DDR) assay to monitor treatment effectiveness in ovarian and prostate cancer patients.

The presentations demonstrate the Parsortix system's potential for personalized cancer treatment and therapeutic monitoring.

Angle PLC announced a study using their Parsortix system to analyze circulating tumor cells (CTCs) from 123 metastatic ovarian cancer patients over two and a half years. The study, the largest of its kind, involved 474 blood samples and identified two key gene markers: ERCC1, linked to worse outcomes, and ESR1, linked to better outcomes. The presence of ESR1 and absence of ERCC1 in CTCs correlated with improved progression-free survival (PFS). This research suggests that molecular characterization of CTCs could be valuable for monitoring ovarian cancer and predicting treatment responses in clinical trials.

ANGLE plc has announced a new commercial agreement with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for prostate cancer studies, worth £550,000. The assay is expected to be completed by Q1 2025 and could provide significant revenue opportunities for the company. The Parsortix system will allow for minimally invasive assessment of the Androgen Receptor status, important in prostate cancer treatment. This agreement further validates ANGLE's technology and potential for long-term revenue growth.